Trials
2 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Allogeneic dual-target CAR-NK cells engineered to enhance tumor recognition and cytotoxicity against heterogeneous solid tumors.”In the company’s words, NCT07744256 on ClinicalTrials.gov
- Tested for
- Small Cell Lung Cancer (SCLC) (2 trials), Relapsed/Refractory SCLC (2 trials), Extensive-stage SCLC, SCLC, Extensive Stage
- Main trialPhase 1/2
- “This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small cell lung cancer (SCLC). Three candidate dual-target constructs (DLL3/CD56, DLL3/GD2, and CD56/GD2) will be assessed during dose escalation; a pre-specified interim assessment will select the most suitable construct to proceed into an expansion cohort at the recommended Phase 2 dose (RP2D).”In the company’s words, NCT07744256 on ClinicalTrials.gov
Other drugs for Small Cell Lung Cancer (SCLC)
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up2
- 14 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 14 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 14 Feb 2027 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | |
| Phase 1/2Recruiting | 14 Feb 2027 | Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026